Status:
UNKNOWN
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Lead Sponsor:
Yonsei University
Conditions:
Muscle-Invasive Bladder Carcinoma
Eligibility:
All Genders
19+ years
Brief Summary
This study is aimed to develop a genome-based platform to predict patients who can achieve bladder preservation after neoadjuvant treatment. The main treatments for invasive bladder cancer are radical...
Detailed Description
The treatment in this study is one of the standard treatments suggested by the NCCN guidelines. Bladder is preserved when neoadjuvant concurrent chemoradiotherapy is performed after transurethral rese...
Eligibility Criteria
Inclusion
- Patients older than 19 years old
- Clinically or histologically diagnosed urothelial carcinoma bladder cancer
- Patients who satisfy all of the following conditions with bladder cancer stage T2-4a, N0-1 according to 8th edition of American Joint Committee on Cancer
- Muscle invasive bladder cancer confirmed by cystoscopy
- Stage T2-4a, N0-1 in CT or MRI
- Performance status 0 or 1 based on ECOG
- Patients agreed to provide the tissue sample obtained from TURB
- Diseases can be evaluated according to RECIST Version 1.1
- Patients who voluntarily agreed to informed consent
Exclusion
- Patients with distant metastasis
- Patients with uncontrolled viral infection (HIV, HBV, HCV)
- Patient who are pregnant, or have possibility of pregnancy and are on lactating
- Hypersensitivity or history of allergic to the drug being used
- Patients with cerebrovascular disease, complications, and infections that are not medically controlled
- Patients with history of other malignant diseases within the past 5 years (excluding cured non-melanoma skin cancer or in situ cervical cancer)
- Those who are taking drugs that can cause drug interactions with chemotherapy
- Patients who withdraw consent
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04686149
Start Date
January 1 2021
End Date
December 1 2024
Last Update
December 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei Severance Hospital
Seoul, South Korea